The schedule of assessments is the single largest driver of what a clinical trial costs. Every visit, procedure, sample, and data point is multiplied across participants, sites, and months, and each one appears somewhere in a CRO proposal as monitoring time, data management effort, site payments, or laboratory fees. Sponsors who review their protocol for cost before the RFP goes out receive proposals that are easier to compare, and they avoid paying for data they will never use.
How does protocol design turn into cost?
The chain is direct. Visits drive investigator grants and coordinator time. Procedures drive pass-through costs for imaging, laboratory work, and specialized testing. Data points drive the size of the case report form, the volume of queries, and the monitoring effort needed to review them. Eligibility criteria drive screen failure rates, and every screen failure carries its own cost. Study duration drives the monthly project management and oversight fees that continue until the last report is delivered.
Which design choices tend to cost the most?
The number of on-site visits and their length
High-cost procedures such as imaging, biopsies, and specialized assessments
Narrow eligibility criteria that push screen failure rates above 50 percent
Intensive pharmacokinetic or biomarker sampling schedules
Exploratory endpoints that add assessments at many visits
Long follow-up periods after the primary endpoint
The number of countries, each with its own regulatory and startup costs
Why should this review happen before the RFP?
A CRO prices the protocol it receives. If the schedule of assessments changes after award, each change typically returns as a change order, and the revised budget arrives after the advantage of a competitive bid has passed. A design review before the RFP also means every CRO prices the same, leaner study, which makes proposals easier to compare line by line.
How do you review a protocol for cost?
Walk through the schedule of assessments one row at a time with clinical, statistical, operational, and regulatory voices in the room. For each assessment, ask what decision the data will inform and whether it supports the primary endpoint, a key secondary endpoint, participant safety, or a regulatory requirement. Assessments that support none of these deserve a second look. Then ask an experienced site coordinator to walk through a participant's visits, because participant burden shows up later as missed visits, dropouts, and slower enrollment.
What does a single exploratory assessment really cost?
Consider an exploratory biomarker drawn at eight visits for 120 participants across 30 sites. That is roughly 960 samples to collect, process, ship, track, store, and reconcile, plus the kits, courier costs, laboratory analysis, data transfers, and monitoring time needed to confirm every sample. The scientific value may well justify it. The point is to decide with the full cost in view, rather than discovering it in a proposal.
What should stay in the protocol even when it costs more?
Anything that protects participants, answers the primary question, or meets a regulatory expectation belongs in the design regardless of cost. The goal of a cost review is a study designed with intention, where every assessment earns its place. Trimming essential safety monitoring or underpowering the study to save money tends to cost far more later, in a failed readout or a repeat study.
Who should own the cost review?
The sponsor should, with the clinical lead and the person accountable for the budget in the same room. A CRO can offer useful input once it is selected, but by then the price is set. In small companies, a two-hour session with the medical lead, a biostatistician, a clinical operations lead, and an experienced site coordinator is usually enough to identify the five or six assessments worth debating. Record each decision and its rationale, because the same questions will return when investigators, regulators, or a future partner review the protocol.
Keep reading: Running a Critical-to-Quality Workshop That Changes the Protocol
